OBJECTIVES::  According to the current Ecuadorian Constitution, health is a right guaranteed by the State; So it is important to generate a budget impact analysis so as to keep in mind the available alternatives that generate the desired results in the population, but optimizing the use of resources from the perspective of the National Health System. METHODS::  Considering a RA population of 210 in Eugenio Espejo Hospital and of 3000 in Ecuador (0.9% prevalence), the BIA analyzes the cost of the drug, cost of follow-up and administration costs of those drugs available in the NFL (Infliximab and etanercept) vs. tocilizumab. The average weight for an Ecuadorian person from 30-59 years old is 66kg for women and 73kg for men. RESULTS::  Within Eugenio Espejo Hospital, for a total of 201 patients tocilizumab resulted in the least expensive treatment with a total annual cost of $1.773.756 for the institution while the most expensive was etanercept resulting in an annual cost of $2.611.850,28 for the institution. Extrapolating these results to the Ecuadorian population, tocilizumab would generate an annual cost of $26.473.980, infliximab of $31.551.660 and etanercept of $ 38.982.840. CONCLUSIONS::  The reimbursement of tocilizumab would generate savings of $ 838.093 to the hospital and of $ 12.508.860 to the government when compared to etanercept and of $ 340.204,56 to the hospital and of $ $ 5.077.680 to the government when compared to infliximab making tocilizumab the least costly and equally effective option for treating RA in Ecuador.